SBIR-STTR Award

Retrievable Blood Oxygen Carrier System
Award last edited on: 4/9/19

Sponsored Program
STTR
Awarding Agency
NIH : NHLBI
Total Award Amount
$1,352,466
Award Phase
1
Solicitation Topic Code
839
Principal Investigator
Agnes E Ostafin

Company Information

Nanoshell Company LLC

1747 East Beechwood Drive
Layton, UT 84040
   (801) 698-3955
   N/A
   N/A

Research Institution

University of Utah

Phase I

Contract Number: 1R41HL095250-01A1
Start Date: 8/1/09    Completed: 9/30/14
Phase I year
2009
Phase I Amount
$357,318
Responding to ever increasing need for blood substitutes, scientists have developed two types of artificial oxygen carriers (AOC), polymeric hemoglobin and perfluorocarbon based AOC. While they are capable of supplying oxygen to the tissue, their side effects appear to be one of the most serious and difficult to solve problems, and a novel programmatic approach to this issue might be needed to meet the urgent need. The underlying hypothesis of this project is that if an AOC is removed promptly from the circulating blood once it is no longer needed, their side effects will be diminished, and the slow change in oxygen delivery capacity can even stimulate normal erythropoiesis. Nanoshell Company LLC is interested in developing a technology based on a novel shell protected nanosized perfluorocarbon based AOC developed in preliminary work by University of Utah researchers. These materials should navigate well through the small blood vessels and withstand the turbulence of circulation. They seem to have high oxygen and carbon dioxide solubility, quickly exchange them at the tissue and lungs, and may be further coated with short chain polyethylene oxide to resist endocytosis. Because of their high density (2.0 g/ml), they are good candidate for removal by centrifugation. Our calculations suggests that the centrifugal retrieval will require two-steps of continuous flow centrifugation and the goal of this STTR project if for the University of Utah researchers to help devise a scale-up synthesis procedure suitable for the volumes of material that are practically needed by patients, and to identify the parameters needed for their retrieval from blood obtained from a local blood bank. With these results Nanoshell Company, LLC will work with university researchers to design a commercializable, novel tandem continuous flow centrifugal rotor that will enable us to retrieve these AOC from the circulating blood in one-step. The separation system may also be useful to remove other existing perfluorocarbon-based AOCs, and potentially find other market niches in the separation of cells for medical use. Pending a successful conclusion of this STTR Phase I project, Nanoshell Company, and LLC will invest in construction of a high throughput synthesizer for the retrievable AOC, as well as the fabrication of the prototype, tandem continuous flow centrifugal rotor at its Utah research facility. Nanoshell Company, LLC will then negotiate licensing rights for AOC material production, and arrange for biocompatibility and animal testing in Phase II of this project to prove efficacy and the reduction of side effects with the implementation of retrieval, in animal models, and will contract consultants to assist in the design testing procedures needed to obtain eventual FDA approval for the use of this technology.

Public Health Relevance:
The goal of this STTR project is to develop a retrievable artificial oxygen carrier (AOC) material and an optimized centrifugal retrieval system that can be safely used to recover the AOC from the circulating blood of patients once the clinical urgency has passed.

Public Health Relevance Statement:
The goal of this STTR project is to develop a retrievable artificial oxygen carrier (AOC) material and an optimized centrifugal retrieval system that can be safely used to recover the AOC from the circulating blood of patients once the clinical urgency has passed.

NIH Spending Category:
Bioengineering; Hematology; Nanotechnology

Project Terms:
Abscission; Acute; Adverse effects; Analysis, Cost; Anemia; Animal Model; Animal Models and Related Studies; Animal Testing; Animals; Apoplexy; Artificial Erythrocytes; Blood; Blood Banks; Blood Circulation; Blood Substitutes; Blood Vessels; Blood, Artificial; Bloodstream; Body Tissues; CO2; Capital; Carbon Dioxide; Carbonic Anhydride; Cell Isolation; Cell Segregation; Cell Separation; Cell Separation Technology; Centrifugation; Cerebral Stroke; Cerebrovascular Apoplexy; Cerebrovascular Stroke; Cerebrovascular accident; Chemicals; Chronic; Circulation; Clinical; Clinical Trials; Clinical Trials, Unspecified; Collaborations; Contracting Opportunities; Contracts; Cost Analyses; Cost Analysis; Devices; Disease; Disorder; Endocytosis; Endogenous Nitrate Vasodilator; Endothelium-Derived Relaxing Factor; Equilibrium; Erythrocyte Substitutes; Erythropoiesis; Evaluation; Excision; Extirpation; Fear; Fluorocarbons; Fractionation, Centrifugation; Fright; Goals; Health Sciences; Hemoglobin; Injury; Investigators; Investments; Lead; Legal patent; Licensing; Lung Parenchyma; Lung Tissue; Macrogols; Marketing; Mediation; Medical; Methods; Modeling; Mononitrogen Monoxide; Negotiating; Negotiation; Nitric Oxide; Nitric Oxide, Endothelium-Derived; Nitrogen Monoxide; Nitrogen Protoxide; Nitrogen oxide; O element; O2 element; One Step; One-Step dentin bonding system; Operation; Operative Procedures; Operative Surgical Procedures; Oxygen; PEG; Particulate; Patents; Patients; Pb element; Perfluorocarbons; Phase; Polyethylene Glycols; Polyethylene Oxide; Polyethyleneoxide; Polyoxyethylenes; Problem Solving; Procedures; Production; Recovery; Red Cell Substitutes; Removal; Research Personnel; Researchers; Resistance; Reticuloendothelial System, Blood; Retrieval; Rights; Rupture; STTR; Scientist; Small Business Technology Transfer Research; Solubility; Source; Stroke; Structure of parenchyma of lung; Surgical; Surgical Interventions; Surgical Procedure; Surgical Removal; Survey Instrument; Surveys; Symptoms; System; System, LOINC Axis 4; Technology; Testing; Tissues; Toxic effect; Toxicities; Treatment Side Effects; Universities; Utah; Vascular Accident, Brain; Vascular constriction (function); Vasoconstriction; WHBLOOD; Washington; Whole Blood; Work; balance; balance function; base; biocompatibility; biomaterial compatibility; brain attack; cell sorting; cerebral vascular accident; clinical investigation; combat; density; design; designing; disease/disorder; endothelial cell derived relaxing factor; flu; heavy metal Pb; heavy metal lead; improved; interest; manufacturing facility; meetings; model organism; nano shell; nano sized; nanoshell; nanosized; novel; prototype; public health relevance; research facility; resection; resistant; scale up; side effect; stroke; surgery; therapy adverse effect; treatment adverse effect; vascular

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
$995,148